Logo

About

Why we are solving this problem

Streamline Bio is solving critical challenges in cell and gene therapy (CGT) manufacturing process to make CGT accessible to patients in need. In CGT, end-to-end automation is often hailed as the "holy grail", the solution to all the manufacturing problems and bottlenecks. However, CGT processes are inherently complex, multi-step, and notoriously variable; this makes it extremely difficult to develop an one-size-fits-all automation solution. That’s where we come in. Streamline Bio offers an AI-driven robotics platform that not only automates but is designed to be flexible, machine-agnostic, and fully digital-native.

Meet Our Team

Co-Founder, CEO

Dr. Yu-Shun (LEO) Hsiao, PhD

  • Harvard PhD in computer science, focusing on AI and robotics systems
  • Prior NVIDIA PhD research intern, joint research with NVIDIA robotics, autonomous vehicles, and architecture research teams
  • 10+ publications and patents in AI and robotics
Arel Lidow
Arel Lidow
Co-Founder, CBO

Dr. Yen-Po (Harvey) Chin, MD, PhD

  • Former McKinsey consultant focusing on life science commercial strategy, with a special focus on CGT biotech and CDMO
  • Harvard healthtech innovation fellow focusing on business strategy
  • Clinical doctor + PhD in biomedical informatics + Forbes 30 under 30 Asia awarded serial entrepreneur

Key Strategic Advisors

Dr. Dolores Baksh

Dr. Dolores Baksh, PhD

  • CEO Hyperius Biotech
  • 25+ years in Regen Med / CGT: Expertise in R&D, preclinical, PD, operations/CMC, commercial
  • Strategic Leadership: Led global Life Sciences growth initiatives
  • BD&L & Sales: Closed multi-$MM deals, multi-year collaborations (Pharma/Biotech)
  • Product/Company Launches: In CGT sector (tech and therapy)
  • Financial Management, Diligence & Acquisitions: Oversaw $MM P&L, closed deals
Dr. Rodney Rietze

Dr. Rodney Rietze, PhD

  • Co-founder/CEO, iVexSol, 2018
  • 25+ years in Regen Med + CGT
  • Co-founder, Principal Investigator - Academia Center of Excellence: Queensland Brain Institute
  • Discovery science/Clinical Trials: drug screening, cell therapies
  • Tech Transfer, Commercial Launch: Kymriah, T-Charge
  • Fund Raising: $116M+ capital from various sources: Strategics, Venture, PE, HNW investors

Core Team Members

Cole Wu Seipel

Cole Wu Seipel

Head of Automation

Cole Wu Seipel, Led a 7M dollars factory automation project.

Melvin Liu

Melvin Liu

Senior Mechanical Engineer

Melvin Liu, 6 years of experience in mechanical design.

Larry Huang

Larry Huang

Senior Software Engineer

Larry Huang, an experienced cloud-native software engineer on building SaaS platform.